Clinical trialNCT02392676WithdrawnPhase 3Interventional

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

SponsorAstraZenecaEnrollment0Platinum Sensitive Relapsed Ovarian Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Olaparib administered as monotherapy in the maintenance setting improves progression free survival compared to placebo in patients whose tumours carry loss of function (deleterious or suspected deleterious) somatic BRCA mutations or loss of function (deleterious or suspected deleterious) mutation in non-BRCA Homologous Recombination Repair (HRR) -associated genes who have a complete or partial response to platinum-based chemotherapy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Carol Aghajanian, MD
MSKCC
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Charlie Gourley, Prof.
University of Edinburgh
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Peru

Research Site
Chiclayo, Peru
Research Site
Lima, Peru

Philippines

Research Site
Quezon City, Philippines

South Korea

Research Site
Goyang-si, South Korea
Research Site
Seongnam-si, South Korea
Research Site
Seoul, South Korea

United Kingdom

Research Site
Birmingham, United Kingdom
Research Site
Cambridge, United Kingdom
Research Site
Coventry, United Kingdom
Research Site
Edinburgh, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Oxford, United Kingdom
Research Site
Sutton, United Kingdom

United States

Research Site
Mobile, Alabama, United States
Research Site
Phoenix, Arizona, United States
Research Site
Los Angeles, California, United States
Research Site
Stanford, California, United States
Research Site
Augusta, Georgia, United States
Research Site
Park Ridge, Illinois, United States
Research Site
Iowa City, Iowa, United States
Research Site
Louisville, Kentucky, United States
Research Site
Covington, Louisiana, United States
Research Site
Scarborough, Maine, United States
Research Site
Baltimore, Maryland, United States
Research Site
Albany, New York, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Olaparib →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jul 2016
Primary completion: 30 Jun 2019
Completion: 30 Jun 2019
Last update posted: 2 May 2016
Registered enrollment: 0
Registry id: NCT02392676

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.